摘要
Abstract
Objective To investigate the efficacy of metformin combined irbesartan in obesity patients with moderate hypertensive and effects on blood sugar,observe the efficacy and safety of metformin combined irbesartan. Methods 80 cases hypertensive patients with moderate obesity treated in our hospital from June 2011 to June 2015 were selected,according to the chronological order of admission were randomly divided into a control group and an observation group. Control group were treated with irbesartan in the treatment of obesity moderate hypertension, the observation group further received metformin, with 2 months in treatment period. The clinical efficacy of the two groups was compared. Results The blood pressure of the observation group was better than that in the control group, the differences were statistically significant(P<0.05). Before the treatment, preprandial blood glucose, postprandial blood glucose, body mass index of patients between the two groups were not significantly different(P > 0.05), after treatment, the differences of fasting blood glucose, postprandial blood glucose, body mass index between the two groups were significant(P < 0.05). And blood biochemical indices in patients with cholesterol, triglyceride, low density lipoprotein were lower than that in the control group, the difference was statistically significant(P < 0.05). Conclusion Using metformin combined irbesartan in treatment of obese hypertensive patients with moderate blood pressure, glycemic control, lipids index has significant clinical effect, no adverse reactions, safety, reliable, and worthy of promotion.关键词
二甲双胍/厄贝沙坦/肥胖/中度高血压Key words
Metformin/Irbesartan/Obesity/Moderate hypertension分类
医药卫生
